76 results about "Vancomycin" patented technology

The invention discloses an application of a small molecule compound DK419 in preparation of a drug for resisting staphylococcus infection, and the CAS number of the small molecule compound DK419 is 2102672-22-8; the staphylococcus comprises at least one of staphylococcus aureus, staphylococcus epidermidis, staphylococcus hominis, staphylococcus capitis and staphylococcus haemolyticus. According to the technical scheme, the novel medical application of DK419 is disclosed, DK419 has the effects of inhibiting growth of staphylococcus and killing staphylococcus aureus, the antibacterial effect is better than that of first-line antibiotic vancomycin, and the bactericidal effect is equal to that of vancomycin; the DK419 has the effect of efficiently removing a biofilm; the DK419 can play a role in resisting staphylococcus aureus infection in an in-vivo skin infection model.

The invention belongs to the technical field of biology, and particularly relates to bifidobacterium longum subsp.infantis FMBL B250020GXY for metabolizing breast milk oligosaccharide and application of the bifidobacterium longum subsp.infantis FMBL B250020GXY, the bifidobacterium longum subsp.infantis FMBL B250020GXY is preserved in China Center for Type Culture Collection on September 1, 2025, and the preservation number is CCTCC M 20251931; three kinds of breast milk oligosaccharides, namely 2 '-fucosyllactose (2'-FL), lactose-N-neotetraose (LNnT) and lactose-N-tetraose (LNT), can be metabolized; plant source carbohydrates such as fructo-oligosaccharide and synanthrin can be metabolized; the compound has a relatively strong capability of removing DPPH and ABTS free radicals; a good inhibition effect is achieved on common pathogenic bacteria; good tolerance to acid and cholate is achieved; the strain is sensitive to gentamicin, streptomycin, tetracycline, chloramphenicol and vancomycin; the compound can be used for preparing antioxidant products, medicines for inhibiting pathogenic bacteria, infant foods and fermented foods, and has a wide application prospect.

The invention discloses a micro-fluidic chip system for detecting staphylococcus aureus and escherichia coli and a detection method. The micro-fluidic chip system comprises a micro-fluidic chip, vancomycin modified iron oxide magnetic nano particles (Fe3O4-Van MNPs), silver (at) aure-4-mercaptobenzoic acid-staphylococcus aureus aptamer nano particles (Ag (at) Au-MBA-Apt NPs) and silver (at) aure-5 '5-dithiobis (2-nitrobenzoic acid)-escherichia coli aptamer nano particles (Ag (at) Au-DTNB-Apt NPs), and the micro-fluidic chip system comprises a micro-fluidic chip, a magnetic nano particle (Fe3O4-Van MNPs), a magnetic nano particle (Ag (at) Au-MBA-Apt NPs) and a magnetic nano particle (Ag (at) Au-MBA-Apt NPs), wherein the micro-fluidic chip integrates a magnetic capture unit, a composite structure construction unit and an SERS in-situ detection unit, and the micro-pipeline is provided with a plurality of necks and cylindrical baffles. When the micro-fluidic chip system is used for detecting the staphylococcus aureus and the escherichia coli in the blood, the sensitivity is high, and the limit of detection (LOD) of the staphylococcus aureus and the escherichia coli is as low as 2.01 FU / mL and 3.28 CFU / mL respectively.

The invention belongs to the technical field of biological medicines, and particularly relates to a cyclic ester peptide compound, a producing strain thereof, a preparation method and application of the cyclic ester peptide compound in preparation of antibacterial medicines. The invention provides a cyclic ester peptide compound as shown in a formula I, a stereoisomer, a tautomer and an isotope derivative of the cyclic ester peptide compound, or a pharmaceutically acceptable salt of the cyclic ester peptide compound, a producing strain Streptomyces alboflavus sp.NX-12 of the cyclic ester peptide compound, and fermentation, separation and purification methods of the cyclic ester peptide compound and the stereoisomer, the tautomer and the isotope derivative of the cyclic ester peptide compound. The cyclic ester peptide compound has strong inhibitory activity on a variety of gram-positive bacteria, can be used for preparing antibacterial drugs, shows application potential in treatment of infection and other related diseases, and compared with the existing similar gram-positive bacterium-resistant glycopeptide antibiotic vancomycin, the cyclic ester peptide compound has the advantages that the cyclic ester peptide compound can be used for preparing the antibacterial drugs; the cyclic ester peptide compound disclosed by the invention has an equivalent antibacterial effect. The preparation method of the cyclic ester peptide compound is simple in process, short in time consumption, capable of greatly reducing the medicine cost and suitable for large-scale production. # imgabs0 #

The present invention relates to the technical field of pharmaceutical compounds and specifically discloses a selenocyanine pregnenol ketamide compound having the following general structural formula: #imgabs0#. The selenocyanine pregnenol ketamide compound of the present invention exhibits strong inhibitory activity against human breast cancer cells, cervical cancer cells, ovarian cancer cells, and human liver cancer cells. Furthermore, the selenocyanine pregnenol ketamide compound of the present invention also exhibits strong inhibitory effects against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The selenocyanine pregnenol ketamide compound of the present invention has low toxicity to humans and exhibits strong inhibitory effects against cancer cells and various drug-resistant bacteria at low concentrations. It can be used to prepare cancer treatment drugs and as an antibacterial agent against drug-resistant bacteria.

The application discloses a material for preventing tissue adhesion and hemostasis and a preparation method thereof, and relates to the technical field of medical biomaterials.The carboxymethyl cellulose, chitosan and vancomycin / ceftazidime are synergistically matched, so that the three functions of hemostasis, adhesion prevention and antibiosis are integrated;meanwhile, the water absorption and gelation of the carboxymethyl cellulose and the blood coagulation activation of the chitosan can jointly strengthen the hemostasis effect; the tissue barrier function of the chitosan and the gel isolation of the carboxymethyl cellulose can jointly improve the adhesion prevention performance; the broad-spectrum antibiosis of the vancomycin and the ceftazidime can respond to the infection risk in different surgical scenes; the material preparation process is simple, the dosage form can be adjusted according to different surgical scenes, the material has good biocompatibility and can be completely degraded, the problem that the existing medical materials have single function and are difficult to meet the needs of complex surgical wounds is solved, and the material has significant clinical application value.

The invention relates to the technical field of materials for preventing and treating local infection, in particular to drug-loaded composite nanoparticles as well as a preparation method and application thereof. The drug-loaded composite nanoparticles provided by the invention comprise hollow polydopamine grafted with vancomycin and lipoic acid-quaternary ammonium salt ionic liquid loaded into a cavity of the hollow polydopamine. In the invention, the HPDA nanoparticles have a hollow structure, and the structure provides sufficient space for loading of drug molecules. The lipoic acid-quaternary ammonium salt ionic liquid can generate heat energy under the microwave heat effect, and bacteria are effectively killed. Besides, under microwave stimulation, the lipoic acid-quaternary ammonium salt ionic liquid not only can enhance the sterilization effect, but also can reduce inflammatory response caused by bacterial infection through the synergistic effect of microwave heat effect and chemical sterilization.

The invention discloses antibiotic-loaded in-situ modified platelet-rich fibrin gel as well as a preparation method and application thereof. The antibiotic-loaded in-situ modified platelet-rich fibrin gel is prepared from the following components in percentage by mass: 88 to 92 percent of PRF (platelet-rich fibrin) matrix, 5 to 8 percent of antibiotic and 3 to 4 percent of modifier, the PRF matrix comprises platelets, leukocytes and fibrin, the antibiotic is vancomycin or gentamicin, and the modifier is a zinc ion-containing compound or quaternized chitosan. The gel can be applied to preparation of chronic infection wound dressing, the antibiotic loading rate of the gel is increased, the gel has the slow release characteristic, the accumulative release within 7 days is 82.3 + / -5.6%, the burst release within 24 hours is less than 15%, the wound healing speed is increased by 40%, and the biological membrane clearance rate is 100%.

The application discloses a food-borne pathogenic bacteria detection method based on composite nanomaterials and belongs to the technical field of food safety detection. The method is characterized by the following steps: synthesizing cerium-based nanomaterial DPA-Ce-GMP with enzyme-like activity based on Ce(CH3COO)3, guanosine-5'-monophosphate disodium (GMP) and 2,6-pyridine dicarboxylic acid (DPA); taking Prussian blue as a carrier; using vancomycin to identify gram-positive bacteria; and constructing a composite nanomaterial PB@DPA-Ce-GMP@Van with targeting and oxidase characteristics, namely PCV. The PCV can be precisely adsorbed on the surface of gram-positive bacteria to form a PCV / gram-positive bacteria composite. The residual PCV in the supernatant after centrifugation can quench the fluorescence of scopolamine (SC) and increase the fluorescence intensity of fluorescent red dye (AR) at the same time. The fluorescence intensity ratio (SC / AR) is used as a detection signal output. The application realizes a composite nanometer platform for rapid detection of bacteria, has high sensitivity and strong anti-interference ability, and has a detection range of 10 1 ~ 10 7 CFU / mL and a detection limit of 5 CFU / mL.

The invention relates to the technical field of biology, in particular to a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. The invention provides a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. A broad-spectrum bacteriophage lyase mutant nucleic acid release liquid containing protein with an amino acid sequence as shown in SEQ ID NO: 1 is adopted; the compound can efficiently act on two important clinical drug-resistant bacteria, namely methicillin-resistant staphylococcus aureus MRSA and vancomycin-resistant enterococcus VRE, at the same time. Through unique molecular design and preparation process optimization, the lyase shows excellent synchronous wall breaking capacity, cell wall destruction can be completed in an extremely short time, and the nucleic acid release efficiency is remarkably superior to that of a traditional method.

The application discloses a kind of smelly danchang dots and preparation method and application, belong to medical technical field.The preparation method of smelly danchang dot includes: smelly danchang fine powder is dispersed in distilled water, and is stirred pyrolysis on heating table;Pyrolysis product is diluted with distilled water, and supernatant is obtained by centrifugation, filter membrane filtration, dialysis, freeze-drying, to obtain carbon dot.The average particle size of obtained carbon dot is 4.51±1.04nm.The smelly danchang dot prepared in the application shows strong inhibitory activity to a variety of gram-positive bacteria (such as listeria, methicillin-resistant staphylococcus aureus MRSA) and fungi (such as Candida albicans), especially to clinically tricky drug-resistant strains, such as vancomycin-resistant enterococci (VRE) and MRSA effective, can be applied to the preparation of antibacterial drugs, antibacterial dressing, disinfectant or preservative, with the advantages of wide raw material source, simple preparation method, low cost, environment-friendly and the like.

This invention discloses the application of the bacterial fission protein FtsZ inhibitor DB1 in the preparation of drugs against drug-resistant bacteria, belonging to the field of drug development technology. The inhibitor provided by this invention is compound DB1, named 3-(2,8-dibromo-10,11-dihydro-5H-dibenzo[b,f]azapheno-5-yl)-N,N-dimethylpropylamine hydrochloride, with the molecular formula C2. 19 H 24 Br2ClN2. This compound, DB1, exhibits significant inhibitory effects against various drug-resistant bacteria, particularly vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus (MRSA), and can significantly improve the susceptibility of methicillin to MRSA. The discovery of compound DB1 provides new ideas and technical support for the preparation of drugs against drug-resistant bacteria.

The invention belongs to the technical field of detection of pests in food, and particularly relates to a rapid staphylococcus aureus detection method based on a nano double-fluorescent probe. The method comprises the following steps: synthesizing carbon dots, preparing silicon nanoparticles, carrying out surface functional modification (introducing vancomycin and an antibody), and constructing a ratio-type fluorescent biosensor. The prepared sensor has double emission fluorescence peaks (492 nm and 529 nm), is good in repeatability and high in sensitivity, and quantitatively analyzes the content of staphylococcus aureus by measuring the ratio (F492 / F529) of the two fluorescence peaks. The detection linear range is wide, and the correlation regression coefficient can reach 0.98. The standard recovery rate in actual sample detection is 94-102.9%, and the relative standard deviation is less than 5%. The method is high in specificity and excellent in anti-interference capability, can be widely applied to rapid, accurate and quantitative detection of staphylococcus aureus in complex matrixes such as dairy products and the like, and has a wide application prospect.

The invention relates to a double-probe detection kit for detecting staphylococcus aureus in meat products and a preparation method of the double-probe detection kit, and belongs to the technical field of food safety. The double-probe detection kit is composed of a magnetic capture probe reagent and a double-signal nano-enzyme probe reagent which are independently packaged and have the same volume; the magnetic capture probe reagent is a vancomycin modified reticular magnetic bead and is used for specifically binding staphylococcus aureus in a meat product detection sample and carrying out separation and enrichment treatment; the double-signal nano-enzyme probe reagent is a blue fluorescent carbon dot modified by a nucleic acid aptamer and is used for specifically combining the staphylococcus aureus subjected to separation and enrichment treatment and generating a staphylococcus aureus concentration dependent colorimetric signal and a fluorescent signal. According to the invention, mutual verification is carried out between dual-mode signals, so that the accuracy of a detection result is improved; according to the method, the detection time is within 1.5 h, the detection time is short, the detection sensitivity is high, and the method has good specificity for common type strains.

The invention belongs to the technical field of high-performance polypropylene, and discloses an antibacterial polypropylene composite material, a preparation method thereof and a medicine bottle. The antibacterial polypropylene composite material is prepared from polypropylene, composite antibacterial particles, a lubricant and the like. Wherein the polypropylene accounts for 78-87.3%, the composite antibacterial particles account for 10-18%, the lubricant accounts for 1-2%, the antioxidant accounts for 0.5-2%, the flexibilizer accounts for 1-3%, and the nucleating agent accounts for 0.2-0.3%. The antibacterial polypropylene composite material disclosed by the invention has very high antibacterial property and mechanical property. The antibacterial polypropylene composite material not only has an antibacterial effect on common bacteria such as escherichia coli and staphylococcus aureus, but also has remarkable antibacterial activity on drug-resistant bacteria such as vancomycin-resistant enterococcus faecalis (VRE) and methicillin-resistant staphylococcus aureus (MRSA), and the outstanding antibacterial characteristic of the antibacterial polypropylene composite material is shown.

Provided herein are compositions to treat Clostridioides difficile (C. difficile), Mycobacterium tuberculosis (M. tuberculosis) and Enterococcus faecalis (E. faecalis). These compositions are related to the known compounds (+)-Puupehenone and (+)-ent-Chromazonarol, which are both naturally occurring products. The new compositions were shown to potently inhibit both growth and toxin production of C. difficile as well as inhibit the growth and survival of both replicating and dormant M. tuberculosis. In the United States the C. difficile burden is approximately 453,000 hospital cases and 29,000 deaths annually. Globally, about 10 million people fall ill from tuberculosis and 1.4 million died from the disease. In addition, the known compound (+)-ent-Chromazonarol (10) was found for the first time to strongly inhibit the growth of E. faecalis. E. faecalis has grown drug resistant to vancomycin. In 2017, Vancomycin-Resistant Enterococci (VRE) caused an estimated 54,500 infections among hospitalized patients and 5,400 estimated deaths in the United States.

The invention discloses an aromatic polyketone compound as well as a preparation method and application thereof. The compound GaB (3) has an effect of treating infection of multiple drug-resistant bacteria. The compound is obtained by being separated from a secondary metabolite of the symbiotic Streptomyces sp.QHH-9511 of licheniformis, and the compound 2, the compound 3, the compound 4 and the compound 5 are new compounds. According to the present invention, the research results show that the GaB can effectively sterilize a variety of drug-resistant bacteria (methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, carbapenem-resistant acinetobacter baumannii, multi-drug-resistant pseudomonas aeruginosa, multi-drug-resistant salmonella, and the like); in addition, the compound has the characteristics of broad-spectrum sterilization, biofilm formation inhibition and low-frequency drug resistance, and can be combined with other antibiotics to cope with super bacteria. Mechanism research shows that GaB is combined with glucosamine-6-phosphate synthetase (GlmS) to prevent synthesis of cell walls so as to play an antibacterial role, and a plurality of constructed living body models show that the compound can effectively reduce the content of bacteria in a body and promote wound repair and has in-vivo medication safety. The research result shows that the GaB can be used as a safe and effective novel pilot natural active small molecule for resisting infection of multiple drug-resistant bacteria.

Compositions and methods are provided for the synthesis and use of biguanide-conjugated antibiotics, which provide a generalizable strategy for rapidly synthesizing potent antibiotics derived from clinically relevant agents.

The invention discloses a screening culture medium and a preparation method and application thereof, the screening culture medium comprises a basic culture medium and additives, and the additives comprise amphotericin B, vancomycin, ox bile salt, sodium deoxycholate and No.3 bile salt. According to the screening culture medium provided by the invention, a special infectious microbe inhibitor is added on the basis of a trisaccharide iron culture medium, so that most gram-negative enterobacter, staphylococcus aureus and part of fungi except salmonella enteritis subspecies and shigella cannot grow; the interference of the infectious microbes on the detection of the salmonella enteritis subspecies and the shigella is avoided, so that the fluorescent probe can be applied to the detection of the salmonella enteritis subspecies and the shigella in a clinical anus swab, and the sensitivity of color development is improved.

The invention discloses a betulinic acid derivative as well as a synthesis method and application thereof. According to the betulinic acid derivative, the carboxyl position of betulinic acid C-28 is subjected to structural modification, and four halogenated aniline derivatives are obtained. Wherein the derivatives b, d and e show strong activity on staphylococcus aureus, the derivatives d and e also show strong activity on vancomycin-resistant staphylococcus aureus (VRSA), and the derivative o strongly inhibits streptococcus pneumoniae. Compared with a parent skeleton, the four derivatives show significantly enhanced antibacterial efficacy. Experimental data prove that the derivatives d and e and further derivatives thereof may provide a promising strategy for resisting drug-resistant gram-positive pathogens, and the derivative d can be further developed into a novel therapeutic agent for biofilm-mediated drug-resistant infection.

The application belongs to the technical field of high-performance polypropylene, and discloses an antibacterial polypropylene composite material, a preparation method thereof and a medicine bottle. The antibacterial polypropylene composite material is prepared from polypropylene, composite antibacterial particles, a lubricant and the like; wherein the polypropylene is 78-87.3%, the composite antibacterial particles are 10-18%, the lubricant is 1-2%, the antioxidant is 0.5%-2%, the toughening agent is 1%-3%, and the nucleating agent is 0.2%-0.3%. The antibacterial polypropylene composite material has high antibacterial performance and mechanical performance. In addition to having antibacterial effects on common bacteria such as Escherichia coli and Staphylococcus aureus, the antibacterial polypropylene composite material has significant antibacterial activity on drug-resistant bacteria such as vancomycin-resistant Enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA), which shows the outstanding antibacterial characteristics of the antibacterial polypropylene composite material.

The invention belongs to the technical field of medicines, and relates to a naphthalimide compound as well as a preparation method and application thereof. The naphthalimide compound or the pharmaceutically acceptable salt of the naphthalimide compound has a structure as shown in a general formula (I) or a general formula (II), wherein # imgabs0 # n is any integer from 0 to 6; the naphthalimide compound provided by the invention is simple in structure, has good antibacterial activity on various bacteria, and particularly has remarkable antibacterial activity on vancomycin moderate drug-resistant bacteria.

The application discloses an antibody-antibiotic conjugate and application thereof, and a structural formula of the antibody-antibiotic conjugate is shown as formula (I) and is composed of a payload antibiotic, a monoclonal antibody targeting Kdo monosaccharide and an enzyme-sensitive linker; the antibody-antibiotic conjugate has strong affinity to Kdo antigen and can be combined with Staphylococcus aureus of different serotypes. Enzymatic treatment of the antibody-antibiotic conjugate can release free antibiotics to improve the bactericidal efficiency on Staphylococcus aureus; the antibody-antibiotic conjugate can effectively kill intracellular bacteria which are difficult to be affected by traditional small-molecule antibiotics through the mediation of the antibody; in the application of a Staphylococcus aureus-induced mouse pneumonia and nephritis model, the antibody-antibiotic conjugate can effectively remove bacteria in the lung and kidney, and the therapeutic effect is better than that of vancomycin. Therefore, the antibody-antibiotic conjugate has potential application in the development of Staphylococcus aureus infection drugs.

The present invention discloses a Vibrio vulnificus selective culture medium and a preparation method thereof. The culture medium comprises a basal culture medium and additives; the basal culture medium comprises peptone, beef extract powder, sodium chloride, potassium chloride, a long-chain alkyl sulfate anionic surfactant or nisin, D-cellobiose, an acid-base indicator, and agar; the additive is tellurite; and the solvent is water. When the basal culture medium contains nisin, the additives further comprise vancomycin, amphotericin B, and polymyxin E. The Vibrio vulnificus selective culture medium of the present invention has high growth selectivity, effectively inhibits the growth of Gram-positive bacteria, effectively inhibits fungal growth, and is sensitive and specific for detecting Vibrio vulnificus. Furthermore, the preparation method does not require autoclaving and avoids the inconvenience of preparing the high-content component, cellobiose, into a sterile additive prior to use, making it more convenient.

The invention belongs to the technical field of organic synthesis, and provides a honokiol phosphine salt derivative as well as a preparation method and application thereof, and a novel magnolol derivative is designed and synthesized by integrating a cationic head group and a hydrophobic chain. The compound shows potent activity (MIC = 1-4 [mu] g / mL) on a series of gram-positive bacteria, meanwhile, the hemolytic activity is extremely low (HC50 = 106.9 [mu] g / mL), and the cytotoxicity is also low (CC50 = 19.25 [mu] g / mL). In addition, the derivative also has the capabilities of rapid sterilization, low drug resistance, good plasma stability and capability of inhibiting biofilm formation and destroying mature biofilms. And compared with vancomycin, the vancomycin-containing antibacterial peptide has the advantage that the bacterial load can be obviously reduced.

The invention relates to the technical field of biological medicines, in particular to application of tri17 peptide subtillis and combination of the tri17 peptide subtillis and vancomycin in preparation of a medicine for resisting vancomycin-resistant enterococcus. The triticin has high bacteriostatic activity on vancomycin-resistant enterococcus, and the bacteriostatic activity of the triticin and vancomycin combined use is higher than that of the vancomycin with the same dosage independently used in the combined use of the triticin and vancomycin combined use of the triticin and vancomycin combined use of the triticin and vancomycin combined use. A trace broth dilution method, a chessboard method minimum inhibitory concentration test, an in-vitro bacterial growth curve and a fluorescent quantitative PCR test prove that the antibacterial activity of vancomycin is synergistically enhanced by the tripeptide tripeptide. The invention provides a novel application of triticin in reversing the drug resistance of vancomycin, which can solve the technical problems of low drug resistance and therapeutic index of clinical vancomycin and the like.

The application discloses a strain of Flammulina velutipes, a fermentation liquor of the strain and application thereof, and belongs to the technical field of microorganisms.The Flammulina velutipes strain R12 is preserved in the Guangdong Provincial Microbial Culture Collection Center on August 18, 2025, the address of the preservation center is No. 59 Building, 5th Floor, Guangzhou Xianlie Middle Road 100, and the preservation number is GDMCC NO. 66855.The fermentation liquor of the Flammulina velutipes strain R12 disclosed by the application has a specific bacteriostatic effect on vancomycin moderately drug-resistant Staphylococcus aureus XN108, and provides an important candidate substance for development of a new type of anti-Staphylococcus aureus drug.

Provided are antibacterial phages that selectively kill bacteria having a drug resistance gene or the like. Antibacterial phage for this includes CRISPR-Cas13a with a target sequence that recognizes a specific gene as a target. This target sequence is designed as a spacer sequence for crRNA of 14-28 bases. Specific genes are drug resistance genes and toxins. The drug resistance genes are included in bacterial genomes and / or plasmids having one or any combination of the group including: methicillin-resistant Staphylococcus aureus, vancomycin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, penicillin-resistant pneumococcus, multidrug-resistant Pseudomonas aeruginosa, multidrug-resistant Pseudomonas aeruginosa, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant cephalosporins, third-generation cephalosporin-resistant Pseudomonas aeruginosa, third-generation cephalosporin-resistant E. coli, and fluoroquinolone-resistant E. coli.

The application discloses a chromogenic differential culture medium for separating duck Riemerella anatipestifer and application thereof, and belongs to the field of microorganism detection. The application provides the chromogenic differential culture medium based on physiological and biochemical characteristics of the duck Riemerella anatipestifer, and the chromogenic differential culture medium takes polymyxin B and vancomycin as specific antibiotics and takes X-Glu as a chromogenic substrate. The experimental results show that the chromogenic differential culture medium can efficiently inhibit growth of miscellaneous bacteria, and the duck Riemerella anatipestifer colony presents a characteristic color, so that the dual functions of selective culture and rapid identification are realized; the duck Riemerella anatipestifer identification method developed based on the chromogenic differential culture medium has the advantages of good selectivity, intuitive identification, simple operation, accurate results and the like, and the application provides new materials and methods for identification of the duck Riemerella anatipestifer and diagnosis of duck Riemerella anatipestifer disease.

The application discloses a series of eugenol-quaternary phosphonium salt conjugates and antibacterial application thereof. The series of compounds are obtained by introducing a quaternary phosphonium salt fragment on a phenolic hydroxyl group of eugenol as a leading compound, so that a series of eugenol-quaternary phosphonium salt conjugates are obtained, and the structural general formula is shown in the following formula (I). The series of compounds exhibit excellent antibacterial activity, and the inhibitory activity on common gram-positive bacteria such as staphylococcus aureus and enterococcus faecium and methicillin-resistant staphylococcus aureus is equivalent to that of vancomycin, a glycopeptide antibiotic. Through structural modification, the water solubility and antibacterial activity of eugenol are improved, and the hemolytic toxicity and cytotoxicity are relatively low. Therefore, the eugenol-quaternary phosphonium salt conjugate has the potential to be further developed as a new type of antibacterial drug.